A 28-year-old woman presents with a 2-day history of severe epistaxis and gum bleeding. She has a history of easy bruising since childhood. On examination, she has petechiae on the lower extremities and a palpable spleen. Hemoglobin is 9.2 g/dL, WBC 7,500/μL, and platelet count 8,000/μL. Peripheral blood smear shows no schistocytes. Coagulation studies and fibrinogen are normal. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** This patient has immune thrombocytopenia (ITP) presenting with severe thrombocytopenia (platelet count 8,000/μL), active mucosal bleeding (epistaxis, gum bleeding), petechiae, and normal coagulation studies. The absence of schistocytes excludes thrombotic microangiopathy (TTP/HUS), and normal fibrinogen excludes DIC. ## Why IVIG is the Most Appropriate Next Step **High-Yield:** In acute ITP with life-threatening or severe bleeding (platelet count < 10,000/μL with active mucosal hemorrhage), **IVIG 1 g/kg/day for 2 days** is the preferred immediate intervention because: 1. **Rapid onset:** IVIG produces a platelet rise within **24–48 hours**, significantly faster than corticosteroids (which take 3–5 days to show effect). In a patient with active epistaxis and platelet count of 8,000/μL, speed of response is critical. 2. **Mechanism:** IVIG saturates Fc receptors on splenic macrophages, blocking phagocytosis of antibody-coated platelets, thereby rapidly increasing circulating platelet counts. 3. **ASH Guidelines (2019):** For newly diagnosed ITP with severe bleeding, IVIG (with or without corticosteroids) is recommended over corticosteroids alone when a rapid platelet rise is needed. ## Management Algorithm for Acute Severe ITP | Severity | Preferred Treatment | |----------|-------------------| | Platelet < 10,000 + active bleeding | IVIG ± corticosteroids (rapid response needed) | | Platelet 10,000–30,000, no major bleeding | Corticosteroids alone (prednisolone 1 mg/kg/day) | | Refractory / chronic ITP | Rituximab, TPO-RA, splenectomy | ## Why Not the Other Options? | Option | Rationale | |--------|-----------| | Corticosteroids alone (Option C) | Onset of action is 3–5 days — too slow for a patient with platelet count of 8,000/μL and active mucosal bleeding. Appropriate for less severe presentations. | | Plasma exchange (Option B) | Indicated for TTP (ADAMTS13 deficiency with schistocytes). No schistocytes here; this is ITP, not TTP. | | Bone marrow biopsy (Option D) | Not the immediate next step; reserved for atypical presentations, age > 60, or when secondary causes need exclusion. Diagnosis here is clinically clear. | **Clinical Pearl:** IVIG and corticosteroids are often used together in severe ITP, but when forced to choose the single best next step in a patient with platelet count < 10,000 and active bleeding, IVIG is preferred for its faster platelet-raising effect (Harrison's Principles of Internal Medicine, 21st ed.; ASH 2019 ITP Guidelines). **High-Yield:** Platelet transfusion in ITP is generally avoided unless there is life-threatening hemorrhage (e.g., intracranial bleed), as transfused platelets are rapidly destroyed by the same autoimmune mechanism. IVIG is the bridge therapy of choice.